DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150291

Efficacy and safety of triple drug fixed-dose combination of telmisartan, amlodipine and hydrochlorothiazide in the management of hypertension

Maccha S. Balraj, Arif A. Faruqui

Abstract


Background: High blood pressure (BP) is the most prevalent chronic disease in India and its prevalence is rapidly increasing among urban and rural populations. This study was conducted to assess the efficacy and safety of triple drug fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorothiazide 12.5mg.

Methods: 30 hypertensive patients having systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 mmHg who were uncontrolled on dual drug therapy with Telmisartan-Amlodipine or Telmisartan-Hydrochlorothiazide combinations were enrolled in this study. The treatment period was of 120 days and patients were administered once daily fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg. Patients were evaluated on 30th, 60th and 120th days of treatment.

Results: There was statistically significant (p<0.0001) decrease in systolic blood pressure from baseline to 30th, 60th and 120th day of treatment mean±SD (157.0±8.68 mmHg vs 148.7±8.19, 137.3±7.84, and 127.0±7.02 mmHg) respectively. Similarly the diastolic blood pressure (DBP) was significantly (p<0.0001) reduced from the baseline to the 30th, 60th and 120th day of treatment (100.0±6.43 mmHg vs. 96.0±6.21, 86.6±6.06 and 80.6±2.53 mmHg respectively).

Conclusion: Thus triple drug fixed dose combination of Telmisartan, Amlodipine and hydrochlorothiazide was found to be effective and safe option for the optimal management of hypertension.

 


Keywords


Diastolic, Systolic, Blood Pressure, Hypertension, Triple drug fixed dose combination

Full Text:

PDF

References


Gupta R, Guptha S. Strategies for initial management of hypertension. Indian J Med Res. 2010;132:531-42.

NICE Clinical Guidelines, No. 127, National Clinical Guideline Centre (UK). London: Royal College of Physicians (UK); 2011 Aug.

Current Science. 2009;97(3).

Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–15.

Mancia G, De Backer G, Dominiczak A. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (European Society of Hypertension) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.

Norris K, Neutel JM; Emerging Insights in the First-Step Use of Antihypertensive Combination Therapy. J Clin Hypertens (Greenwich). 2007;9(12Suppl5):5-14.

Mancia G, Laurent S, Agabiti-Rosei E. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27(11):2121–58.

Doménech M, Coca A. Role of triple fixed combination valsartan, amlodipine and hydrochlorothiazide in controlling blood pressure. Patient Prefer Adherence. 2010;4:105–13.

Khemchandani D, Faruqui AA. Efficacy & safety of oral triple drug combination of telmisartan, amlodipine and hydrochlorothiazide in the management of non-diabetic hypertension. IJRR. 2013;1(2):37-41.

Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-8.

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

Alleman Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with uncontrolled hypertension with previous monotherapy: The Exforge in previous failure after single therapy (EX-fast) study. J Clin Hypertens. 2008;10:185–94.

Pool JL, Glazer R, Weinberger M, Alvarado M, Huang J, Graff A. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25 versus monotherapy: a double blind placebo controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29:61–73.

Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.

Bhattacharya S, Faruqui AA. Efficacy and Safety of Triple Drug Fixed-Dose Combination of Telmisartan, Amlodipine and Hydrochlorothiazide in the Management of Hypertension. Pac J Med Sci. 2014;13(1):43-51.

Bhatt AK, Faruqui AA. Management of Hypertension with Fixed-Dose Triple Drug Combination of Telmisartan, Amlodipine and Hydrochlorothiazide. Int J Clin Surg Adv. 2014;2(1):12-20.